CELL AND GENE THERAPY
Enara Bio | December 09, 2020
Enara Bio, a biotechnology organization utilizing its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver focused on cancer immunotherapies, announces its extension and move to the new Bellhouse Building at The Oxford Science Park. Enara Bio's move from the Oxford BioEscalator to one of the UK's biggest biomedical advancement habitats is in anticipation of its future development and desire to change malignancy care. The devoted exploration office will empower the organization to quicken the preclinical improvement of its lead MR1-targeting on T-cell therapy program while continuing to drive the disclosure of novel disease antigens and TCRs for immunotherapy.
The move, which will see the organization possess more than 5,000 sq. ft of office and laboratory space in the Bellhouse Building, is a key milestone in Enara Bio's development and improvement. The reason fabricated office will empower Enara Bio to unite key faculty with world-driving abilities in bioinformatics, immunopeptidomics, cell therapy measure development, and immunology to discover and develop novel TCR-based immunotherapies.
Resilience | June 07, 2022
National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture will advance its work within a culture of academic innovation alongside industrial expertise.
The Cell Therapy Manufacturing Center will be based in a state-of-the art 60,000-square-foot manufacturing facility in the Texas Medical Center, with a team of 70 employees focused on process and analytical development as well as early-phase and clinical-stage Good Manufacturing Practices (GMP).
The joint venture combines MD Anderson’s expertise in immunotherapy and cell therapies as well as a leading clinical trials infrastructure, with Resilience’s innovative biomanufacturing technologies, advanced analytics and a national network for developing and producing cell therapies. Together, the parties aim to accelerate the path of cell therapies to the clinic, while enabling scalability and a smooth transition to late-phase clinical and commercial activities.
Cell therapies have had a dramatic impact for patients with certain cancers, but progress has been hampered by structural challenges, This novel joint venture was conceived to address those challenges by harnessing the complementary capabilities of two world-class organizations, allowing us to advance innovative programs to deliver impactful therapies to patients.”
Jason Bock, Ph.D., Chief Executive Officer of the Cell Therapy Manufacturing Center.
The joint venture will engage with MD Anderson researchers and external industry collaborators to advance new therapies through preclinical and clinical development, ensuring consistent and safe products that can be evaluated rapidly in clinical trials led by MD Anderson physicians. Resilience customers will be able to leverage this offering as part of the company’s growing network of biomanufacturing facilities that are flexible enough to scale projects from small-batch pre-clinical to large-scale commercial production. Resilience has 10 facilities across North America, with more than 1 million square feet of manufacturing space.
The promise of cell therapies to help patients in need has been limited by a lack of innovation in biomanufacturing, This collaboration aims to overcome those hurdles by extending our network with this unique partnership, creating opportunities to incubate innovative ideas and provide cutting-edge biomanufacturing technologies and processes to researchers, with a goal of bringing more cell therapies to patients.”
Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience.
The joint venture will advance the most promising cell therapy modalities to answer unmet clinical needs, including engineered tumor infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR)-modified T cells, endogenous T cells (ETCs), engineered natural killer (NK) cells and other emerging technologies, for patients with hematological and solid tumors. MD Anderson researchers are leaders in the field of cancer cell therapy, responsible for advancing the translational and clinical development of many of the currently approved and experimental cell therapies.
The joint venture is built upon MD Anderson’s Biologics Development platform, formerly part of the institution’s Therapeutics Discovery division. Current strategic collaborations with MD Anderson’s Biologics Development platform will continue; collaborative relationships with MD Anderson’s Therapeutics Discovery division, as well as physicians and scientists across the institution, also will be maintained.
We believe in the tremendous potential of cell therapies to deliver solutions that offer cures, not merely prolonged survival. Resilience offers unique capabilities that make it an ideal choice for unlocking that potential and accelerating impactful cell therapies, Our mission at MD Anderson is to end cancer, and this joint venture is a strategic step toward realizing that goal.”
Ferran Prat, Ph.D., J.D., senior vice president for Research Administration and Industry Relations at MD Anderson.
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development.
Sartorius Stedim Biotech | December 10, 2020
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million U.S. dollars in 2020 at solid development rates and a generous twofold digit EBITDA edge. The gatherings conceded to a price tag of roughly 27 million U.S. dollars in addition to a procure out segment of up to 9 million U.S. dollars, contingent upon the accomplishment of characterized deals revenue growth by 2023.
This official statement contains forward-looking articulations about the future development of the Sartorius Stedim Biotech Group. Forward-looking proclamations are liable to known and obscure dangers, vulnerabilities and different elements that could make real outcomes vary substantially from those communicated or suggested by such explanations. Sartorius Stedim Biotech accepts no risk for refreshing such articulations considering new data or future occasions. This is an interpretation of the first French-language public statement. Sartorius Stedim Biotech will not assume any risk for the accuracy of this translation. The first French official statement is the legally binding version.